key: cord-0713750-4cy5ucw7
authors: Palich, R.; Veyri, M.; Vozy, A.; Marot, S.; Gligorov, J.; Benderra, M.-A.; Maingon, P.; Morand-Joubert, L.; Adjoutah, Z.; Marcelin, A.-G.; Spano, J.-P.; Barrière, J.
title: High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated by chemotherapy for solid cancers
date: 2021-06-22
journal: Ann Oncol
DOI: 10.1016/j.annonc.2021.06.018
sha: d27b4cd56bbd7e64cd750c3e92521faf2d06e51c
doc_id: 713750
cord_uid: 4cy5ucw7

nan

Anti-spike antibody titer (UA/mL) Anti-spike antibody titer (U/mL)

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Weak immunogenicity after a single dose of SARS

CoV-2 mRNA vaccine in treated cancer patients

anti-SARS-CoV-2 vaccine in patients treated for solid tumors

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. The Lancet